Do GLP-1 Weight Loss Drugs Increase Thyroid Cancer Risk? Current Evidence Review
Review examines the connection between GLP-1 drugs (semaglutide, tirzepatide) and thyroid cancer, finding that while animal data raised concerns, human evidence does not support a significant increase in thyroid cancer risk.
Quick Facts
What This Study Found
Rodent thyroid tumor findings do not appear to translate to humans. Large-scale human data shows no significant increase in thyroid cancer with GLP-1 drug use.
Key Numbers
Data covered 2004 through Q1 2024 from FAERS. Reporting odds ratios were calculated for thyroid cancer across weight-loss medication categories.
How They Did This
Review of preclinical thyroid C-cell data, species differences in GLP-1R expression, clinical trial safety data, and pharmacovigilance reports for GLP-1 drugs.
Why This Research Matters
The thyroid cancer warning on GLP-1 drugs concerns millions of patients and clinicians. Clarifying that the rodent risk does not translate to humans provides important reassurance.
The Bigger Picture
The disconnect between rodent and human thyroid responses to GLP-1 drugs is one of the best-studied examples of species-specific drug effects. Understanding these differences is critical for evidence-based risk communication to patients.
What This Study Doesn't Tell Us
Thyroid cancer is slow-growing; long-term follow-up (>10 years) is limited. Medullary thyroid cancer is very rare, limiting statistical power. The boxed warning remains appropriate for patients with MTC family history.
Questions This Raises
- ?Should the FDA thyroid cancer boxed warning be modified based on human evidence?
- ?Is very long-term (>10 year) GLP-1 drug use associated with any thyroid changes?
- ?Should routine thyroid monitoring be recommended for GLP-1 drug users?
Trust & Context
- Key Stat:
- Rodent risk does not translate Human thyroid C-cells have far fewer GLP-1 receptors than rodents, and clinical data shows no significant thyroid cancer increase
- Evidence Grade:
- Moderate evidence: review of species-specific biology and large-scale human safety data, though very long-term follow-up is limited.
- Study Age:
- Published in 2025. Most current assessment of GLP-1 drug thyroid cancer concerns.
- Original Title:
- Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.
- Published In:
- Endocrinology, diabetes & metabolism, 8(2), e70038 (2025)
- Database ID:
- RPEP-09748
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs cause thyroid cancer?
In rats, GLP-1 drugs caused thyroid tumors. However, human thyroid cells respond very differently — they have far fewer GLP-1 receptors. Large-scale human data shows no significant increase in thyroid cancer. The boxed warning reflects animal data, not confirmed human risk.
Should I get my thyroid checked while on semaglutide?
Routine thyroid cancer screening is not recommended specifically for GLP-1 drug users. However, report any new thyroid lumps, difficulty swallowing, or hoarseness to your doctor. Avoid GLP-1 drugs if you have a personal or family history of medullary thyroid cancer.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09748APA
Abi Zeid Daou, Christophe; Aboul Hosn, Omar; Ghzayel, Lana; Mourad, Marc. (2025). Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.. Endocrinology, diabetes & metabolism, 8(2), e70038. https://doi.org/10.1002/edm2.70038
MLA
Abi Zeid Daou, Christophe, et al. "Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database.." Endocrinology, 2025. https://doi.org/10.1002/edm2.70038
RethinkPeptides
RethinkPeptides Research Database. "Exploring Connections Between Weight-Loss Medications and Th..." RPEP-09748. Retrieved from https://rethinkpeptides.com/research/abi-2025-exploring-connections-between-weightloss
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.